Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and Clinical Trial Agreements (Tables)

Sponsored Research and Clinical Trial Agreements (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of research and development for sponsored research and clinical trial agreements

For the three and nine months ended September 30, 2020 and 2019, Aevitas recorded the following expense in connection with its sponsored research and clinical trial agreements:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
($ in thousands)	2020		2019		2020		2019
UMass - adeno-associated virus ("AAV")		163		—		218		—
UPenn - AAV		—		255		567		755
Duke - AAV		—		17		—		17
Total	$	163	$	272	$	785	$	772

Mustang [Member]

Schedule of research and development for sponsored research and clinical trial agreements

For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
($ in thousands)	2020		2019		2020		2019
City of Hope National Medical Center	$	—	$	500	$	500	$	1,500
CD123 (MB-102)		48		269		344		1,028
IL13Rα2 (MB-101)		96		244		422		811
Manufacturing		—		114		—		343
CS1 (MB-104)		65		—		835		—
Beth Israel Deaconess Medical Center - CRISPR		—		—		—		69
St. Jude Children's Research Hospital - XSCID (MB-107)		107		—		1,665		—
Fred Hutchinson Cancer Research Center - CD20 (MB-106)		418		49		1,134		690
Total	$	734	$	1,176	$	4,900	$	4,441